tbuckley/cabot-search huggingface dataset:
PWE-125 Managing The Malignant Polyp: Surveillance or Surgery?
Authors: Z Cargill, A Masding, R Raju, S Mann
Journal: Gut (2016)

<h3>Introduction</h3> A ‘malignant polyp’ contains cancer cells that have breached the mucosa. Usually this refers to a polyp that is resected endoscopically and appears benign, but contains carcinoma on histological analysis. A reported 0.75–5.6% of polyps removed at colonoscopy are malignant.<sup>1</sup> However practice is varied regarding subsequent management. Options include colonoscopic surveillance or surgery, utilising criteria to estimate the risk of cancer spread following polypectomy versus the risk of surgery. <h3>Methods</h3> Patients were identified from the colorectal cancer multidisciplinary team (MDT) database. Endoscopy, histology and clinic letters were reviewed from the Electronic Patient Record. Information collected included patient demographics, polyp histology, the degree of cancer differentiation and invasion, whether surveillance or surgery was utilised, the rate of residual malignancy identified within surgical specimens and 1 year mortality.The aim was to determine the management and outcome of patients with malignant polyps in our institution over a 3 year period (2010–13). <h3>Results</h3> Our institution is in a district hospital which serves a population of 500,000 in North London. Twenty patients were identified (M = 12; mean age 60 yrs; range 53–80 yrs). Estimated polyp size ranged from 3 mm to 20 mm [pedunculated = 9 (45%); sessile = 11 (65%)]. All polyps were adenocarcinomas [well differentiated = 1 (5%); moderately differentiated = 15 (75%); poorly differentiated = 1 (5%); highly suspicious of malignancy, but managed as malignant polyps = 3 (15%)]. Lymphovascular invasion was present in only 1 case (5%). Resection margins were clear in 9 patients (45%), positive in 4 (20%) and indeterminate in 7 (35%). Ten patients (50%) underwent surgery: 5 (50%) had a laparoscopic anterior resection, 3 (30%) had a laparoscopic hemicolectomy and 2 (20%) had Transanal Endoscopic MicroSurgery (TEMS). The surgical resection specimens failed to identify any residual malignancy on histology in 7 cases (70%). Two patients (10%) died of unrelated causes over a 12 month follow-up (surgical management = 1, endoscopic management =’1). <h3>Conclusion</h3> In our unit, half of all patients with a malignant polyp had subsequent surgery with its associated risks. However 70% of those patients had no residual microscopic malignancy in the resected specimen. We feel that these patients would be best served in a dedicated ‘Polyp MDT’ where the colonoscopist contributes to the discussion. Experienced endoscopists can be confident about the completeness of resection even in the presence of histological uncertainty, thereby avoiding unnecessary surgery. All patients in the colonoscopy surveillance pathway have been free of cancer recurrence during the period of follow-up. <h3>Reference</h3> 1 Williams JG, et al. Management of the malignant colorectal polyp: ACPGBI position statement. Colorectal Disease 15.s2 (2013): 1–38. <h3>Disclosure of Interest</h3> None Declared
A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results
Authors: Robert J. Kreitman, Martin S. Tallman, Steven Coutre, Tadeusz Robak, Wyndham H. Wilson, Maryalice Stetler-Stevenson, Pierre Noel, David J. FitzGerald, Manuela Buzoianu, Robert J. Lechleider, Ira Pastan
Journal: Blood (2010)
STEM-05GPR133 IS ENRICHED IN GLIOBLASTOMA STEM CELLS AND REGULATES THE RESPONSE TO HYPOXIA
Authors: N. Sumru Bayin, J. Robert Kane, Aram S. Modrek, Nadim Shohdy, Doug MacNeil, David Zagzag, Dimitris G. Placantonakis
Journal: Neuro-Oncology (2015)

Intratumoral heterogeneity in glioblastoma (GBM) is exemplified by the diversity of tumor microenvironments, which include normoxic hypervascular areas and necrotic regions, which are considered hypoxic. GBM stem cells (GSCs) play a central role in tumor growth and therapy resistance. How GSCs adapt to diverse GBM microenvironments remains an important and unanswered question. We recently discovered that CD133-expressing GSCs are metabolically adept at expanding in hypoxic conditions and do not require Notch signaling for their self-renewal. Transcriptional analysis indicated that CD133+ GSCs have 17.8 ± 8.8-fold enriched expression of GPR133 (n = 3 biospecimens), a member of the adhesion family of G protein-coupled receptors. Immunostaining with GPR133 antibody revealed that GPR133 expression is restricted to hypoxic regions within GBM tumors (12/12 GBM biospecimens) and not present in normal brain. We observed that GPR133 mRNA expression correlates with hypoxia-induced transcripts, such as CA9 and VEFGA (n = 3 primary cultures). To test the hypothesis that GPR133 expression is regulated by oxygen tension, we subjected GBM cultures to 1% O2 in vitro and found that GPR133 transcript was consistently upregulated (n = 5 cultures). To examine whether GPR133 is important for GSC self-renewal, we tested the effect of shRNA-mediated knockdown on in vitro tumorsphere formation ability. GPR133 knockdown depleted CD133+ GSCs and inhibited tumorsphere formation under both normoxic and hypoxic conditions (p < 0.05). GPR133 knockdown also reduced in vivo tumorigenicity and increased survival of implanted mice (n = 3). Using colorimetric assays, we found that CD133+ GSCs have 26.2 ± 12.53% higher cAMP levels compared to CD133- GBM cells (n = 3) and that GPR133 knockdown downregulated cAMP levels to 47.25 ± 27.27% of scramble control (n = 3), suggesting that GPR133 signals through activation of adenylate cyclase and cAMP elevation.
Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity.
Authors: Robert Lowsky, Keith Stockerl-Goldstein, Ginna Laport, David Miklos, Sally Arai, Judith Shizuru, Laura Johnston, Karl Blume, Robert Negrin, Samuel Strober
Journal: Blood (2006)
AB0621 From Vedoss To Established Systemic Sclerosis Diagnosis According To The New ACR/EULAR 2013 Classification Criteria: A French-Italian Capillaroscopic Survey
Authors: M. Vasile, J. Avouac, I. Sciarra, K. Stefanantoni, N. Iannace, Y. Allanore, V. Riccieri
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> NailfoldCapillaroscopy (NC) is a diagnostic and sensitive tool in order to investigate Raynaud9s phenomenon (RF) that is the hallmark of both Systemic Sclerosis (SSc) and Very Early Diagnosis Of ScS (VEDOSS) patients. Thus NC is largely used in patients with these conditions and NC specific abnormalities have become a minor criteria in ACR/EULAR SSc Criteria in 2013. <h3>Objectives</h3> Aim of our study was to monitor NC changes in a group of 66 VEDOSS patients, enrolled in two EUSTAR center. <h3>Methods</h3> We selected those patients who developed SSc at the follow-up. Moreover, we compared the NC features of these patients with NC of those VEDOSS patients who did not move to SSc, in order to find out NC features, if any, suitable as predictive risk factor for SSc at the time of VEDOSS diagnosis. <h3>Results</h3> In our 66 VEDOSS patients, 21 of them (19 females, mean age 55 yrs) shifted to SSc in a mean follow-up time of 31 months (range 6–60 months). Table 1 shows the main features of matched VEDOSS patients: Group A with unchanging diagnosis and Group B progressing into SSc. Table 2 shows the progression of NC abnormalities from VEDOSS to established SSc diagnosis in Group B patients. When we compared basal NC of Group A and Group B patients, in former VEDOSS developing SScwe found a significantly higher NC score (&gt;1), 13 versus 5 cases (p&lt;0.03) and a larger mean apex width, 177 μm (range 50–640) versus 104 μm (range 10–280) (p&lt;0.005). <h3>Conclusions</h3> Our study describes a progression of NC changes during the evolution of early SSc. Moreover we identified some NC features, such as higher NC score and larger apex width, whose presence at the very early diagnosis of SSc may suggests its development in an established disease, thus underlying the relevance of specific NC abnormalities as possible predictive risk factors. <h3>Disclosure of Interest</h3> None declared
High Incidence of Neurological Complications in Patients with Sickle Anemia Disease Undergoing Related Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: Early Diagnosis and Treatment Can Chance the Prognosis
Authors: Ricardo Helman, Juliana Folloni Fernandes, Michelli Silva Diniz, Fabio R. Kerbauy, Lucila Nassif Kerbauy, Eduardo Cerello Chapchap, Melina Brumatti, Nathalia da Silva Halley Neves, Alessandra Prandini Azambuja, Jose Mauro Kutner, Andreza Feitosa Ribeiro, Nelson Hamerschlak
Journal: Blood (2014)
FRI0271 Performance of Modified Rodnan Skin Score in Early Diffuse Cutaneous Scleroderma–Analysis from 4 Cohorts: Table 1
Authors: D. Khanna, S. Produman, T. Frech, S. Nihtyanova, R. Domsic, V. Berrocal, W. Stevens, M. Nikpour, C. Denton
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The modified Rodnan skin score (mRSS) is used as a primary outcome measure in clinical trials of dcSSc. EUSTAR analysis has proposed that a lower mRSS and earlier disease duration are associated with progressive disease, as defined by worsening mRSS [1]. <h3>Objectives</h3> 1. To find an optimal cut off for worsening mRSS in 4 cohorts of dcSSc, and 2. To assess if presence of anti-RNA polymerase III [RNAP] vs. anticentromere /or anti-SCL-70 is associated with different mRSS cut off for worsening disease. <h3>Methods</h3> We used 4 cohorts with early dcSSc (defined as ≤60 months from 1st non-RP sign or symptom) – 2 US cohorts [Combined Response Index in Systemic Sclerosis [CRISS] and Prospective Registry in Early Systemic Sclerosis [PRESS]], the UK Royal Free Hospital [RFH] cohort, and the Australian Scleroderma Interest Group [ASIG] cohort. Inclusion criteria included dcSSc diagnosed by a scleroderma physician, mRSS data at 2 time points (12±3 months apart), and availability of disease duration (defined as 1st non Raynaud phenomenon sign or symptom). Worsening of skin fibrosis was defined as increase in mRSS &gt;5 points and ≥25% from baseline to 2nd visit. To identify the optimal cut point of baseline MRSS that yields the highest sensitivity for worsening disease, we developed the ROC curves. For worsening of mRSS, we fitted logistic regression model with worsening as outcome variable and a binary variable of baseline mRSS cut point as predictor. We also explore the differences between the proportion of patients with worsening of mRSS among the patients with presence of RNAP vs. anticentromere /or anti-SCL-70 and tested using proportion z-test. <h3>Results</h3> There were 235 patients with early dcSSc included in the analysis. Mean (SD) disease duration was 26.61 (14.67) months, median=23.67 months. We evaluated 3 cut points for disease duration based on inclusion criterion from recent clinical trials: ≤24, 36, and 60 months. For all disease durations, approximately 10.5% of patients had mRSS worsening at 1-year period. A mRSS cut off of 26 had the highest probability of worsening (Table). mRSS of ≤26 was able to enrich worsening mRSS from 10.5% to 15.0% for different cut points but excluded 33–35% of patients with early dcSSc. 64 patients (27.23%) had RNAP and 48 (20.43%) had anti-centromere and anti-SCL-70 and there was no difference in cut off for worsening of mRSS at 1-year. <h3>Conclusions</h3> In this preliminary analysis, a mRSS≤26 was the optimal cut point for worsening disease in 4 cohorts with dcSSc. This threshold gained an additional 5% of patients who worsened but excluded 33–35% of patients with early dcSSc. <h3>References</h3> Maurer B Ann Rheum Dis 2015 <h3>Disclosure of Interest</h3> None declared
Abstract 4631: The Cytochrome P450 Inhibitor Fluconazole Increases Plasma Concentrations of R-, and S-Warfarin but not ATI-5923, a Novel VKOR Inhibitor
Authors: Ian Irwin, Daniel M Canafax, Dave Ellis, Peter Milner, Pascal Druzgala
Journal: Circulation (2008)

Warfarin (WARF) is a Vitamin K epoxide reductase (VKOR) inhibitor and oral anticoagulant widely used for prevention and/or treatment of stroke associated with atrial fibrillation. In spite of proven efficacy, WARF therapy is limited by numerous drug-drug interactions (DDIs). Of these, many involve inhibition of it’s cytochrome P450 (CYP) mediated metabolism, leading to increased drug exposure and risk of bleeding. ATI-5923 was created with the goal of producing a VKOR inhibitor that was non-oxidatively hydrolyzed by esterases to an inactive metabolite (ATI-5900) and thereby reduced likelihood of DDIs and maintain the benefits of WARF. We hypothesized that, unlike warfarin the pharmacokinetics (PK) of ATI-5923 is not subject to DDI with the CYP 2C9/3A4 inhibitor fluconazole (FCZ). Two groups (n=10/group) of healthy volunteers were randomized to receive a single equipotent oral doses of either WARF (17.5 mg) or ATI-5923 (50 mg). ATI-5923, ATI-5900, R-WARF and S-WARF concentrations were measured in serial plasma samples collected over a 7 day period and the PK parameters (AUC, C max , T max and T1/2) were determined. On day 7, subjects were given FCZ (400 mg/day) for 14 days and on day 21, subjects received a second dose of either WARF or ATI-5923 and FCZ was continued for 7 days and the PK study was repeated. Exposure (AUC)for WARF were dramatically increased by FCZ treatment, with the effects being more pronounced on the more active S-isomer: The AUC inf for S-WARF was increased more than 3 fold while this parameter was increased 2 fold for R-warf. Increased exposure appeared to result from reduced clearance: The T 1/2 increased from 48 to 104.3 hrs (R-warf) and from 31 to 87.9 hrs (S-warf). No significant effects of FCZ treatment on ATI-5923 or ATI-5900 exposures or clearance were observed. The dramatic effect of the CYP2C9/3A4 inhibitor FCZ on WARF exposure is consistent with the known CYP-mediated clearance of this drug. In the clinical setting, a corresponding increase in WARF exposures would be expected to increase anticoagulant effects and raise the risk of bleeding. In contrast, ATI-5923 which undergoes non-CYP mediated metabolism, is unaffected by FCZ treatment.
The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells
Authors: Zeyou Wang, Qin Guo, Rong Wang, Gang Xu, Peiyao Li, Yingnan Sun, Xiaoling She, Qiang Liu, Qiong Chen, Zhibin Yu, Changhong Liu, Jing Xiong, Guiyuan Li, Minghua Wu
Journal: Journal of Hematology & Oncology (2016)

As a well-characterized key player in various signal transduction networks, extracellular-signal-regulated kinase (ERK1/2) has been widely implicated in the development of many malignancies. We previously found that Leucine-rich repeat containing 4 (LRRC4) was a tumor suppressor and a negative regulator of the ERK/MAPK pathway in glioma tumorigenesis. However, the precise molecular role of LRRC4 in ERK signal transmission is unclear.The interaction between LRRC4 and ERK1/2 was assessed by co-immunoprecipitation and GST pull-down assays in vivo and in vitro. We also investigated the interaction of LRRC4 and ERK1/2 and the role of the D domain in ERK activation in glioma cells.Here, we showed that LRRC4 and ERK1/2 interact via the D domain and CD domain, respectively. Following EGF stimuli, the D domain of LRRC4 anchors ERK1/2 in the cytoplasm and abrogates ERK1/2 activation and nuclear translocation. In glioblastoma cells, ectopic LRRC4 expression competitively inhibited the interaction of endogenous mitogen-activated protein kinase (MEK) and ERK1/2. Mutation of the D domain decreased the LRRC4-mediated inhibition of MAPK signaling and its anti-proliferation and anti-invasion roles.Our results demonstrated that the D domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells. These findings identify a new mechanism underlying glioblastoma progression and suggest a novel therapeutic strategy by restoring the activity of LRRC4 to decrease MAPK cascade activation.
In Vitro and in Vivo Abrogation of An Erythroid Iron Restriction Developmental Checkpoint by Isocitrate through a Novel Erythropoietin- Coupled Signaling Mechanism
Authors: Grant C. Bullock, Lorrie L Delehanty, Anne-Laure Talbot, Chante Richardson, Kamaleldin E Elagib, Adam Goldfarb
Journal: Blood (2008)
Pyruvate dehydrogenase has a major role in mast cell function, and its activity is regulated by mitochondrial microphthalmia transcription factor
Authors: Israa Sharkia, Tal Hadad Erlich, Nadine Landolina, Miri Assayag, Alex Motzik, Inbal Rachmin, Gillian Kay, Ziv Porat, Sagi Tshori, Neville Berkman, Francesca Levi-Schaffer, Ehud Razin
Journal: Journal of Allergy and Clinical Immunology (2016)
Some CLL Cells Bind Myosin-Exposed Apoptotic Cells. Exposure of Cytoplasmic Myosin Results From Transfer of Caspase-3 Dependent Cleavage Products to the Outer Cell Membrane
Authors: Xiaoxuan Cui, Lu Zhang, Amanda R Magli, Rosa Catera, Jonathan E Kolitz, Steven L. Allen, Kanti R Rai, Nicholas Chiorazzi, Charles C Chu
Journal: Blood (2010)
Virtual and Physical Analysis of the Proximal T Cell Signalosome Reveals PP2A Inhibition Is Important for Co-Stimulatory Function of Immunomodulatory (IMiD) Drugs
Authors: Jessica M. McDaniel, Kenyon G. Daniel, Fred Luhder, Sheng Wei, Richard Tanner, Danielle Grams, Alan F. List, P.K. Epling-Burnette
Journal: Blood (2010)
Clinical Trial of a Multitarget EBV PCR Panel In Patients with EBV Positive Malignancies: Correlation of Peripheral Blood EBV Viral Load with Disease Activity
Authors: Vikram R Paralkar, Marin F. Xavier, Anthony R Mato, Gerald Wertheim, Jared Weiss, Sharon Arnoldi, Kenneth Algazy, Steven C Goldstein, Sunita Dwivedy Nasta, Edward A Stadtmauer, Stephen J. Schuster, Donald Tsai
Journal: Blood (2010)
A Phase I Study of Hypofractionated Tailored Total Marrow or Total Lymphoid Irradiation with Helical Tomotherapy Plus Chemotherapy As a Conditioning Regimen for Autologous Stem Cell Transplantation
Authors: G. Pica, S. Vagge, G. Beltrami, S. Nati, G. Catania, R. Corvò, A. M. Carella
Journal: Blood (2011)
Fractionated Osteoblastic Niche Cells Enhances the Homing Activity of Hematopoietic Stem Cells.
Authors: Fumio Arai, Yuka Nakamura, Kentaro Hosokawa, Isao Kobayashi, Hiroko Iwasaki, Yumiko Gomei, Hiroki Yoshihara, Toshio Suda
Journal: Blood (2009)
Ex Vivo Three-Dimensional (3D) Functional biomimicry for the Long-Term Cytokine-Free Culture of Human Primary Acute Myeloid Leukemia (AML)
Authors: Maria Rende, Teresa Mortera-Blanco, Nayef Aqel, Sarah Ryley, Ricardo Morilla, Athanasios Mantalaris, Nicki Panoskaltsis
Journal: Blood (2012)
PWE-074 Variation in The Management of Barrett’s High Grade Dysplasia in England
Authors: G Chadwick, D Cromwell
Journal: Gut (2016)

<h3>Introduction</h3> The British Society of Gastroenterology recommend that patients with Barrett’s high grade dysplasia (HGD) are considered for active treatment, with endoscopic therapy considered the treatment of choice.<sup>1</sup> We sought to investigate patterns of treatment among patients with newly diagnosed HGD in England. <h3>Methods</h3> This study used data collected for the National Oesophago-Gastric Audit (NOGCA) on patients diagnosed with HGD in England between 1<sup>st</sup> April 2012 and 31<sup>st</sup> March 2015. The study looked at the relationship between patient’s initial treatment, and their characteristics and diagnostic process. We also examined patterns of treatment by strategic clinical network (SCN) where the patient was diagnosed. We estimated case-mix adjusted rates of surveillance using logistic regression models. <h3>Results</h3> There were 1,284 patients diagnosed with HGD over 3 years. Mean (SD) age at diagnosis was 71.1 (±10.6) years; 74.1% were men. 795 (65.7%) were managed endoscopically, 66 (5.4%) had an oesophagectomy, and 350 (28.9%) underwent surveillance alone. The proportion of patients managed by surveillance increased with age (p &lt; 0.001), but was not affected by a history of comorbidities (p = 0.981). Patients were more likely to receive active treatment if they were referred from a Barrett’s surveillance program (84.9% vs 59.4%, p &lt; 0.001), or if they had the diagnosis confirmed either by a second pathologist (79.1% vs 57.2%, p &lt; 0.001), or repeat biopsy (78.1% vs 62.1%, p &lt; 0.001). Active treatment was also more common if patients were discussed at a MDT meeting (75.1% vs 53.6%, p &lt; 0.001). After adjusting for age, sex, and history of comorbidities, we observed significant variation across SCNs in the proportion of patients managed by surveillance alone (Figure 1), ranging from 4% to 54%. <h3>Conclusion</h3> A substantial proportion of patients with HGD are managed by surveillance alone. Trusts should review their management of these patients, and consider referring cases to specialist centres for treatment. <h3>Reference</h3> 1 Fitzgerald RC, <i>et al</i>. BSG guidelines on the diagnosis and management of Barrett’s oesophagus. <i>Gut</i> 2014;<b>63</b>(1):7–42. <h3>Disclosure of Interest</h3> None Declared
A Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization of Hematopoietic Stem Cells in Multiple Myeloma Patients.
Authors: Connie A. Sizemore, Justin LaPorte, Melissa Sanacore, H. Kent Holland, Joan Mccollum, Jennifer Westerman, Lawrence E. Morris, Asad Bashey, Scott R. Solomon
Journal: Blood (2009)
Downregulation of the Common Cytokine Receptor Subunit Beta c by Omacetaxine in CML: A Potential Molecular Mechanism to Overcome Cytokine-Mediated Resistance against BCR-ABL-Inhibitors.
Authors: Thomas Klag, Nicolai Härtel, Thomas Schenk, Adam R Craig, Andreas Hochhaus, Paul La Rosee
Journal: Blood (2009)
AB0848 Spinal Pain Is The Main Complaint of Outpatients Seen in Rheumatology in Cameroon, Sub-Saharan Africa
Authors: F. Kemta Lekpa, M.S. Doualla, H. Namme Luma
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The prevalence of spinal pain or back pain among Africans may be comparable to that reported in research undertaken in developed nations. However, studies evaluating the epidemiological characteristics of spinal pain are rare in sub-Saharan Africa (1). <h3>Objectives</h3> To determine the main epidemiological characteristics of spinal pain in a tertiary healthcare center in Cameroon, sub-Saharan Africa; To describe the profile of specific spinal pain found in Cameroon. <h3>Methods</h3> We performed a cross-sectional study among outpatients seen in Rheumatology consultation at Douala General Hospital, Cameroon, between January 2004 and December 2013. All patients followed for spinal pain (pain experienced in all the regions of the spine) were screened. <h3>Results</h3> During the study period, 7024 patients were seen in Rheumatology Department but only 6804 cases (4433 women and 2371 men) were selected for analysis because it had a clearly defined rheumatic disease. The mean age of patients was 52.3±14.3 years. The mean body mass index was 29.3 kg/m<sup>2</sup>±5.1, with 5194 patients with overweight and obesity. The main reason for consultation concerned the peripheral skeleton in 3230 patients (47.5%) and 3574 (52.5%) in the axial skeleton. The pain was present in all patients with axial involvement and was localized in the lumbar spine in 3008 patients (84.2%) [Table 1]. Most cases are nonspecific, but in 223 (6.2%) of cases a specific cause was suspected, especially of infectious origin (Table 2). Indeed, 64 cases of infectious spondylodiscitis were collected. Tuberculosis was suspected in the majority of patients, but only one case had been documented. <h3>Conclusions</h3> Spinal pain, especially in the lumbar region of the spine is the main location of pain in Rheumatology in Cameroon. The infectious and inflammatory etiologies are rare. <h3>References</h3> Louw QA et al. BMC Musculoskelet Disord 2007;8:105. <h3>Disclosure of Interest</h3> None declared